Galapagos NV
GLPGDrugs in Pipeline
15
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How GLPG's past catalysts played out
Filgotinib
Crohn's Disease
GLPG3667
Dermatomyositis
GLPG2222 50 mg
Cystic Fibrosis
GLPG1205
Idiopathic Pulmonary Fibrosis
GLPG3970
Rheumatoid Arthritis
GLPG1837 dose 1
Cystic Fibrosis
GLPG0974
Ulcerative Colitis
GLPG2222 150 mg q.d.
Cystic Fibrosis
GLPG1837 dose 2
Cystic Fibrosis
GLPG1690 600 mg QD
Idiopathic Pulmonary Fibrosis
GLPG0634
Rheumatoid Arthritis
GLPG1690
Systemic Sclerosis
GLPG1972
Osteoarthritis
GLPG2737
Cystic Fibrosis
GLPG0259 oral capsule
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Filgotinib | Phase 3 | Crohn's Disease | - | - |
GLPG3667 | Phase 2 | Dermatomyositis | - | - |
GLPG2222 50 mg | Phase 2 | Cystic Fibrosis | - | - |
GLPG1205 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
GLPG3970 | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG1837 dose 1 | Phase 2 | Cystic Fibrosis | - | - |
GLPG0974 | Phase 2 | Ulcerative Colitis | - | - |
GLPG2222 150 mg q.d. | Phase 2 | Cystic Fibrosis | - | - |
GLPG1837 dose 2 | Phase 2 | Cystic Fibrosis | - | - |
GLPG1690 600 mg QD | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
GLPG0634 | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG1690 | Phase 2 | Systemic Sclerosis | - | - |
GLPG1972 | Phase 2 | Osteoarthritis | - | - |
GLPG2737 | Phase 2 | Cystic Fibrosis | - | - |
GLPG0259 oral capsule | Phase 2 | Rheumatoid Arthritis | - | - |
Cystic Fibrosis
5 drugs in this indication
Rheumatoid Arthritis
4 drugs in this indication
Idiopathic Pulmonary Fibrosis
2 drugs in this indication
Dermatomyositis
1 drug in this indication
Ulcerative Colitis
1 drug in this indication
Crohn's Disease
1 drug in this indication
Systemic Sclerosis
1 drug in this indication
Osteoarthritis
1 drug in this indication
Ankylosing Spondylitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Galapagos NV's drug pipeline?→
CatalystAlert tracks 15 drug candidates in Galapagos NV's (GLPG) pipeline across Phase 3, Phase 2. Its lead program is Filgotinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galapagos NV's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Galapagos NV (GLPG) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GLPG biotech catalysts?→
Add GLPG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galapagos NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.